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Cellular ciliary phenotyping indicates 
pathogenicity of novel variants in IFT140 
and confirms a Mainzer–Saldino syndrome 
diagnosis
Machteld M. Oud1,2* , Brooke L. Latour1,2‡, Zeineb Bakey1,2‡, Stef J. Letteboer1,2, Dorien Lugtenberg1, 
Ka Man Wu1,2, Elisabeth A. M. Cornelissen3, Helger G. Yntema1,4, Miriam Schmidts1,2,5, Ronald Roepman1,2† 
and Ernie M. H. F. Bongers1†
Abstract 
Background: Mainzer–Saldino syndrome (MZSDS) is a skeletal ciliopathy and part of the short-rib thoracic dysplasia 
(SRTD) group of ciliary disorders. The main characteristics of MZSDS are short limbs, mild narrow thorax, blindness, 
and renal failure. Thus far, variants in two genes are associated with MZSDS: IFT140, and IFT172. In this study, we 
describe a 1-year-old girl presenting with mild skeletal abnormalities, Leber congenital amaurosis, and bilateral hear-
ing difficulties. For establishing an accurate diagnosis, we combined clinical, molecular, and functional analyses.
Methods: We performed diagnostic whole-exome sequencing (WES) analysis to determine the genetic cause of 
the disease and analyzed two gene panels, containing all currently known genes in vision disorders, and in hearing 
impairment. Upon detection of the likely causative variants, ciliary phenotyping was performed in patient urine-
derived renal epithelial cells (URECs) and rescue experiments were performed in CRISPR/Cas9-derived Ift140 knock out 
cells to determine the pathogenicity of the detected variants in vitro. Cilium morphology, cilium length, and intrafla-
gellar transport (IFT) were evaluated by immunocytochemistry.
Results: Diagnostic WES revealed two novel compound heterozygous variants in IFT140, encoding IFT140. Thor-
ough investigation of WES data did not reveal any variants in candidate genes associated with hearing impairment. 
Patient-derived URECs revealed an accumulation of IFT-B protein IFT88 at the ciliary tip in 41% of the cells indicative 
of impaired retrograde IFT, while this was absent in cilia from control URECs. Furthermore, transfection of CRISPR/
Cas9-derived Ift140 knock out cells with an IFT140 construct containing the patient mutation p.Tyr923Asp resulted in 
a significantly higher percentage of IFT88 tip accumulation than transfection with the wild-type IFT140 construct.
Conclusions: By combining the clinical, genetic, and functional data from this study, we could conclude that the 
patient has SRTD9, also called Mainzer–Saldino syndrome, caused by variants in IFT140. We suggest the possibility 
that variants in IFT140 may underlie hearing impairment. Moreover, we show that urine provides an excellent source 
to obtain patient-derived cells in a non-invasive manner to study the pathogenicity of variants detected by genetic 
testing.
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Background
Short-rib thoracic dysplasia (SRTD) refers to a group of 
ciliopathies characterized by skeletal abnormalities, that 
are classified into 18 molecular subclasses; SRTD1-16, 
EVC, and EVC2. The majority of genes mutated in SRTDs 
encode intraflagellar transport (IFT) proteins, while a 
small subset encode proteins involved in hedgehog sign-
aling, ciliogenesis, or DNA damage response signaling 
[1–9]. IFT is required for cilium assembly, maintenance, 
and disassembly. Two axonemal transport modules can 
be distinguished: the IFT-B complex, powered by the 
kinesin-2 motor, for transport in anterograde direction 
(from ciliary base to tip), and the IFT-A complex, pow-
ered by the dynein-2 motor, for retrograde transport 
(from ciliary tip to base). Variants in genes encoding 
subunits of the IFT-A particle are associated with SRTD 
types 3–5, 7–9, 11, and 15 [1, 2, 4, 5, 8]. The character-
istic skeletal findings of SRTDs comprise short ribs and 
a narrow thorax and are often combined with short stat-
ure, pelvic deformities, polydactyly, and brachydactyly. 
In addition to the skeletal abnormalities, other organ 
systems can be involved including the kidneys, the liver, 
and the central nervous system [1]. Since the phenotypic 
overlap between different SRTD subclasses is substan-
tial, the classification is based on the underlying genetic 
defect and not on the clinical phenotype. Establishing 
an accurate diagnosis as early as possible is essential to 
provide the best-personalized care for the patient. For 
example, monitoring renal function is likely to be more 
important for patients carrying a pathogenic variant in 
IFT140, TTC21B, or WDR19 than for patients who carry 
DYNC2H1 or IFT80 variants, as the latter two are pri-
marily associated with a skeletal phenotype and IFT140, 
TTC21B, and WDR19 are associated with a skeletal phe-
notype accompanied by renal insufficiency and retinal 
degeneration [2, 10].
The effect of variants in ciliary genes can be studied at 
the protein level by analyzing the ciliary phenotype in 
patient-derived cells. Skin biopsies are commonly used 
to obtain patient-derived fibroblasts; however, this is an 
invasive and painful procedure. In 2015, Ajzenberg et al. 
reported on a non-invasive method to obtain patient-
derived cells from urine [11]. Urine-derived renal epi-
thelial cells (URECs) can be used to study the ciliary 
phenotype and are an excellent alternative for fibroblasts. 
In addition, since the development of cystic kidneys is 
one of the hallmarks of ciliopathies, it is beneficial to 
study the ciliary phenotype in cells that originate from 
this affected organ.
In this study, we describe the use of URECs and 
CRISPR/Cas9 knockout cell lines to determine the 
pathogenicity of two novel missense variants in IFT140 
in a 1-year-old girl clinically diagnosed with a SRTD 
phenotype. By showing defective retrograde transport in 
patient-derived URECs and mutant IFT140 transfected 
CRISPR/Cas9-derived Ift140 knockout cells, we confirm 
the clinical and molecular diagnosis of SRTD9/Mainzer–
Saldino syndrome in this patient.
Methods
Collection of samples
Genomic DNA of patient II-3 was isolated from whole 
blood and used for WES. Urine was collected from the 
patient, her unaffected parents, and three healthy con-
trols to study the ciliary phenotype.
Diagnostic whole‑exome sequencing
Diagnostic WES was performed as described previously 
[12]. In brief, we analyzed the vision disorder gene panel 
(version DG 2.3.2) and the hearing impairment gene 
panel (version DG 2.3.2) [13, 14]. Exonic and intronic 
positions −  20 till +  8 variants with a frequency  <  5% 
in dbSNP,  <  1% in in-house database, and  <  5% in the 
Exome Aggregation Consortium (ExAC) were evalu-
ated and classified based on the guidelines for variant 
classification determined by the Association for Clinical 
Genetic Science (ACGS) [15]. The same filtering strategy 
was used for the analysis of the complete WES dataset.
Urine‑derived renal epithelial cell isolation and culture
The collection of urine, isolation of cells, and culturing 
of URECs was performed as described previously [11]. 
In brief, midstream urine was collected and refriger-
ated for up to 4  h. Cells were retrieved from the urine, 
washed once, and cultured in 1 ml primary UREC culture 
medium consisting of a 1:1 ratio Dulbecco’s Modified 
Eagle’s medium (DMEM): Ham’s F12 Nutrient Mix con-
taining 10% FCS, 0.1 mg/ml Primocin (ant-pm-2, Invivo-
gen, Toulouse, France), and 1× REGM SingleQuots and 
growth factors (CC-4127, Lonza; Basel, Switzerland) in a 
24-well plate. Cells were incubated at 37 °C with 5%  CO2 
and 0.5 ml primary UREC culture medium was added 24, 
48, and 72 h after cell isolation. At 96 h after cell isola-
tion, half of the culture medium was replaced by UREC 
proliferation medium consisting of REBM Basal Medium 
(CC-3191, Lonza; Basel, Switzerland) containing 1× 
REGM SingleQuots and growth factors, and 0.1  mg/ml 
Primocin. Every day for up to 14  days, half of the cul-
ture medium was replaced with fresh UREC proliferation 
medium until the URECs were visible and at approxi-
mately 80% confluence.
Ciliary phenotyping in URECs
To determine the ciliary phenotype of the patient, 
healthy family members, and controls, URECs were 
analyzed for cilium morphology, length, and IFT. 
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Immunocytochemistry was used to visualize the cilia as 
described previously [16]. In short, URECs were cultured 
on glass coverslips until they reached ~ 80% confluence. 
After fixation, permeabilization, and blocking, the cov-
erslips were incubated with primary antibodies targeting 
IFT88 at 1:100 dilution (rabbit, 13967-1-AP, Protein-
tech Group, Manchester, UK), IFT140 at 1:100 dilution 
(rabbit, 17460-1-AP, Proteintech Group), acetylated-α-
tubulin at 1:1000 (mouse, T6793, Sigma-Aldrich, Zwi-
jndrecht, Netherlands), and RPGRIP1L at 1:500 dilution 
(guinea pig, SNC039, homemade [17]). Upon washing, 
the coverslips were incubated with fluor-labeled sec-
ondary antibodies, including goat-anti-mouse IgG Alexa 
Fluor 568 (1:400), goat-anti-rabbit IgG Alexa Fluor 488 
(1:400), and goat-anti-guinea pig IgG Alexa Fluor 647 
(1:400), obtained from Life Technologies (Bleiswijk, The 
Netherlands). Finally, the coverslips were embedded in 
Fluoromount-G (Southern Biotech, Birmingham, AL, 
USA) containing DAPI. Coverslips were microscopi-
cally analyzed with a Zeiss Axio Imager Z2 fluorescence 
microscope (Zeiss, Sliedrecht, Netherlands) equipped 
with an ApoTome slider. Images were obtained with ZEN 
2012 software (Zeiss) and processed with Photoshop CS4 
(Adobe Systems, San Jose, CA, USA) and freely available 
FIJI software.
Generation of CRISPR/Cas9‑derived Ift140 knockout IMCD3 
cells
The CHOPCHOP website (https://chopchop.rc.fas.har-
vard.edu/) was used to design short-guide RNA (sgRNA) 
targeting exon 8 of the Ift140 gene. The designed 
sgRNA-Ift140-E8 targets a single unique site in the 
mouse genome and the negative control sgRNA targets 
a sequence that is not present in the mouse genome. 
The two sgRNA sequences used are sgRNA-ift140-E8: 
ATAAAGGACGAGTAGCTATG and sgRNA-neg-ctrl: 
GCGAGACAGTTTGACCGTCT. Cas9 plasmid pSp-
Cas9 (BB)-2A-GFP (PX458) containing either sgRNAs 
were constructed using the bbsI restriction sites. The 
insertion of the sgRNAs into the plasmid was verified by 
sequencing (data not shown).
Mouse Inner Medullary Collecting Duct 3 (mIMCD3) 
cells were cultured at 37  °C with 5%  CO2 in 1:1 ratio 
DMEM: Ham’s F12 culture medium containing 10% FCS, 
1% sodium pyruvate, and 50  µg/ml penicillin/strepto-
mycin. mIMCD3 cells were transfected with the px458-
Ift140-E8 or the px458-neg-ctrl construct using JetPrime 
according to the manufacturer’s protocol. GFP expres-
sion was checked after 24-, 48-, and 72-h post-trans-
fection. At 72  h post-transfection, cells were harvested 
and prepared for FACS single-cell sorting by passing 
them through a 70-µm syringe Falcon (BD Bioscience). 
Subsequently, single-cell colony expansion occurred 
and genomic DNA was extracted to check for variants 
in Ift140 by Sanger sequencing upon PCR amplifica-
tion of the region around the targeted sequence (Addi-
tional file 1: Figure S2). Immunoblotting was performed 
to validate the knocking out of IFT140 on protein level. 
Protein lysates were made from CRISPR/Cas9 negative 
control cells and CRISPR/Cas9-derived Ift140 knockout 
cells with or without transfection of the IFT140-Myc-
DDK construct (NM_014714, cat# RC207528, OriGene, 
Herford, Germany). The immunoblot was stained with an 
antibody targeting IFT140 (IFT140 antibody was kindly 
provided by Dr. G. Pazour).
IFT140 variant rescue analysis in CRISPR/Cas9‑derived 
Ift140 knockout cells
The CRISPR/Cas9-derived Ift140 knockout cells were 
no longer able to form cilia (Fig. 3b). To study the effect 
of the patient variants in IFT140 on ciliogenesis and 
IFT88 localization, the mIMCD3 CRISPR/Cas9-derived 
IFT140 knockout (mIMCD3-Ift140−/−) cells were cul-
tured on glass coverslips, followed by transfection with 
the wild-type or mutant IFT140-Myc-DDK construct 
(NM_014714, cat# RC207528, OriGene, Herford, Ger-
many) using JetPrime (cat# 114, Polyplus transfection, 
France) according to the manufacturer’s protocol. The 
mutant IFT140-Myc-DDK constructs included either the 
p.Tyr923Asp or p.Tyr332Valfs*18 patient variants. Ciliary 
phenotyping analysis was performed as described in the 
previous section to determine the ability of the wild-type 
and mutant clones to rescue ciliogenesis and retrograde 
IFT.
Results
Clinical examination
The patient was born at term as the second child of a 
non-consanguineous couple from Bangladeshi descent 
(Fig. 1a). The first child was unaffected. The mother had 
previously had a miscarriage at 10-week gestation due 
to an unknown etiology. During the neonatal period, 
the patient presented with bilateral vision and hearing 
difficulties and was seen by a pediatrician. A behavioral 
observation audiometry (BOA) test, at 9 months of age, 
showed a bilateral moderate–severe hearing loss of a 
sensorineural kind necessitating hearing aids [18]. Com-
prehensive ophthalmologic examination at the age of 
7 months diagnosed Leber congenital amaurosis (LCA). 
Diagnostic WES for analysis of the vision disease gene 
panel was requested and the patient was referred to a 
clinical geneticist upon retrieval of the WES results. The 
clinical geneticist performed a follow-up examination at 
1 year of age, which showed mild skeletal abnormalities; 
short stature (−  1.9 SD), mild narrowing of the thorax, 
and brachydactyly of both hands and feet suggestive of a 
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ciliopathy phenotype. In addition, psychomotor develop-
ment was delayed; however, stimulation from the parents 
together with the use of prescription glasses and hearing 
aids contributed to marked improvement in the course 
of her development. There were no signs of renal insuf-
ficiency, or renal cysts on ultrasound at 12 months of age.
Whole‑exome sequencing
To determine the underlying molecular cause of the 
disease, a diagnostic WES analysis was performed. 
The vision disorder gene panel included 337 genes 
known to cause syndromic or non-syndromic blind-
ness [13]. After filtering, 41 candidate variants were 
evaluated and only two variants were classified class 
3 or higher. Both variants were found in IFT140 
(NM_014714.3) HG19:g.1637216 c.992_993dup 
(class 5, clearly pathogenic) and HG19:g.1575889 
c.2767T > G (class 3, unknown significance) correspond-
ing to p.Tyr332Valfs*18 and p.Tyr923Asp in IFT140 
(NP_055529), respectively (Fig.  1). Segregation analy-
sis in the parents showed bi-allelic inheritance that is in 
line with the expected recessive inheritance pattern of 
IFT140-associated ciliopathies. Neither of the IFT140 
variants have previously been described in the literature 
nor are present in the ExAC database (February 2017) 
[19].
To investigate the possibility of a separate genetic cause 
for the progressive hearing impairment present in this 
patient, diagnostic exome hearing impairment gene panel 
analysis of 132 known deafness genes was performed, 
but did not detect any likely pathogenic variants. Sub-
sequently, all detected WES variants were analyzed, but 
no candidate pathogenic variants for hearing impairment 
were found. This suggests that pathogenic variants in 
IFT140 could underlie the hearing impairment present in 
this patient.
Ciliary phenotyping in URECs
To determine the disruptive effect of the p.Tyr332Valfs*18 
and p.Tyr923Asp variants on IFT140 protein function, 
we studied the ciliary phenotype in URECs of the patient 
and her unaffected parents, and compared them to three 
unrelated and unaffected controls (Fig.  2a). The ciliary 
length of the patient’s URECs at passage 2 (3.08 µm) was 
within the range measured in the controls (C1 at passage 
3 = 3.47 µm, C2 at passage 2 = 3.07 µm, C3 at passage 
2 = 4.30 µm) (Fig. 2b). We were able to detect IFT140 in 
primary cilia of the majority (90% or more) of cells from 
the patient, her parents, and three unrelated controls 
(Fig. 2c). Abnormalities were observed when studying the 
localization of the IFT-B protein IFT88. We detected a 
significant accumulation of IFT88 at the ciliary tip in 41% 
of the cells from the patient, and in 5% of the cells from 
the father as well as the healthy sibling II-2 (Fig. 2d). This 
accumulation was not seen in cells from the mother or 
in any of the unrelated controls. The measurements were 
carried out on URECs at passage 1–5. These data suggest 
that even though the mutated IFT140 localizes to the pri-
mary cilium and does not cause ciliogenesis defects, it 
does lead to defective retrograde transport.
IFT140 variant rescue analysis in CRISPR/Cas9‑derived 
Ift140 knockout cells
The protein lysate of mIMCD3-Ift140−/− cells validated 
the absence of IFT140 protein in these cells (Fig.  3a). 
Upon transfection with wild-type or p.Tyr923Asp mutant 
IFT140, a partial rescue of the IFT140 protein level was 
detected. There was no IFT140 signal detected in the 
protein lysate of mIMCD3-Ift140−/− transfected with 
p.Tyr332Valfs*18. To exclude that the observed ciliary 
tip accumulation of IFT88 in patient-derived URECs 
was due to other  variants, we assessed the ability of 
patient mutant IFT140 constructs to rescue ciliogenesis 
and determined the localization of IFT88. Ciliogenesis 
was restored in 11% of the analyzed cells upon rescue 
with wild-type IFT140. Both mutants, p.Tyr923Asp and 
p.Tyr332Valfs*18, rescued ciliogenesis in 6% of the cells 
(Fig.  3b). Defects in retrograde IFT were visualized by 
ciliary tip accumulation of IFT-B protein IFT88. Cilia res-
cued with the p.Tyr923Asp mutant IFT140 showed IFT88 
ciliary tip accumulation in 50%, which is significantly 
more than seen in ciliated cells rescued with wild-type 
IFT140 (23% tip accumulation). A similar phenotype was 
seen in ciliated cells transfected with p.Tyr332Valfs*18 
IFT140 (56% tip accumulation).
Discussion
In this study, we used diagnostic WES to detect vari-
ants in IFT140 as a likely cause of a clinical ciliopathy 
phenotype of the patient and performed cellular ciliary 
phenotyping to investigate the pathogenicity of these 
variants. The classical syndromic phenotype associated 
with variants in IFT140 includes skeletal abnormalities, 
renal disease, and retinal dystrophy. Hearing impair-
ment has been described only once before to be part of 
the IFT140-related ciliopathy spectrum [20], when a 
patient with otherwise non-syndromic retinal dystrophy, 
carrying variants in IFT140, was described with progres-
sive hearing loss. Our patient presented with progres-
sive hearing loss in the neonatal period, and, since the 
majority of congenital hearing loss has a genetic cause, 
we thoroughly investigated the WES data but could not 
detect any likely pathogenic variants in genes associated 
with hearing impairment. Although we cannot exclude 
non-genetic causes to underlie the hearing impairment 
of our patient, it is possible that the detected pathogenic 
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IFT140 variants are causative for this feature, not previ-
ously described in Mainzer–Saldino patients.
Since pathogenic variants in other IFT-A proteins could 
give rise to a similar cellular phenotype, we carefully 
checked the remaining IFT-A and dynein motor com-
plex proteins and could not find any pathogenic variants 
or large homozygous copy number variations (CNVs) 
[21, 22]. In addition, we carefully checked IFT172, as this 
gene is known to give rise to a similar clinical phenotype 
[3], but did not find any (likely) pathogenic changes in 
this gene either. We next evaluated the detected IFT140 
variants (workflow presented in Additional file  1: Fig-
ure S1). IFT140 is part of the IFT-A core subcomplex 
together with IFT122 and WDR19, which combined with 
the peripheral subcomplex, that includes IFT43, WDR35, 
and TTC21B, forms the functional IFT-A complex [23, 
24]. The previous studies have shown that defective ret-
rograde transport causes an accumulation of proteins at 
Fig. 1 Clinical and molecular description. a Pedigree of the patient (II-3), including WES results for variants found in IFT140 (NM_014714.3). b Sche-
matic view of the IFT140 gene (NM_014714.3). IFT140 consists of 31 exons and variants, c.992_993dup and c.2767T > G, detected in patient II-3 were 
found in exon 9 and exon 21, respectively. The published IFT140 variants known to cause a syndromic disease are annotated in grey. c Schematic 
view of IFT140 protein structure (NP_055529). IFT140 consists of 1462 amino acids and has five WD repeats and nine tetratricopeptide repeats (TPR). 
The published IFT140 variants known to cause a syndromic disease are annotated in grey. The two novel IFT140 variants are positioned in the fifth 
WD repeat, p.Tyr332Valfs*18, and in the third TRP repeat, p.Tyr923Asp (black)
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the ciliary tip, and may result in shorter cilia [21, 22, 25, 
26]. We studied URECs from the patient to determine 
whether the novel IFT140 variants caused defective ret-
rograde IFT (workflow presented in Additional file  1: 
Figure S1). We detected defective retrograde IFT in 41% 
of the cilia of the patient’s cells, while this was not seen 
in controls and only in a small percentage of cilia from 
the unaffected sibling and parents. Significant effects 
Fig. 2 Ciliary phenotype in URECs. URECs derived from the patient (II-3) were compared to URECs from three control individuals (C1–3). a Repre-
sentative image of URECs stained for ciliary markers, i.e., acetylated-α-tubulin (red) and RPGRIP1L (green). b Ciliary length measurements based on 
the acetylated-α-tubulin staining of the cilium. The dots represent individual cells and the horizontal line indicates the mean (N ≥ 100). Significance 
was measured using the unpaired two-tailed t test; C1 compared to C2 p < 0.0397; C1 compared to C3 p < 0.0001; C2 compared to C3 p < 0.0001; 
C1 compared to II-3 p < 0.0345; C2 compared to II-3 p < 0.9458; C3 compared to II-3 p < 0.0001. c Presence of IFT140 in the cilium. Parents (I-1 and 
I-2) are included in the analysis. Scale bar represents 5 µm. d Cilia were visualized with acetylated-α-tubulin (red) and RPGRIP1L (pink). The cells were 
analyzed for the presence of IFT88 (green) accumulation at the ciliary tip. Patient II-3 showed a significant accumulation of IFT88 in 41% of the cells 
(Fisher’s exact two-tailed test showed a p < 0.0001 when comparing the cells of the patient to those of the controls). Scale bar represents 5 µm
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Fig. 3 IFT140 variant rescue analysis in mIMCD3-Ift140−/− cells. CRISPR/Cas9-derived Ift140 knockout mIMCD3 (mIMCD3-Ift140−/−) cells were trans-
fected with wild-type, p.Tyr923Asp or p.Tyr332Valfs*18 mutant IFT140-Myc-DDK constructs and the cilium rescue abilities were assessed. Immu-
nofluorescent images are representative for the measurements showing the base of the cilium using RPGRIP1L (pink), an antibody targeting FLAG 
to visualize the IFT140-Myc-DDK construct (red), and IFT88 in green. Scale bar represents 2 µm. a Immunoblot analysis of IFT140 protein levels in 
CRISPR/Cas9 negative control mIMCD3 cells and CRISPR/Cas9-derived Ift140 knockout mIMCD3 cells in the absence or presence of the IFT140-Myc-
DDK construct. The immunoblot was stained with an antibody targeting IFT140. b Ciliogenesis measurements in untreated mIMCD3-Ift140−/− cells 
and after transfection with wild-type or mutant IFT140-Myc-DDK constructs. Untreated mIMCD3-Ift140−/− cells showed < 1% ciliogenesis. Transfec-
tion with the wild-type IFT140 construct rescued ciliogenesis in 11% of the analyzed cells, while both mutant IFT140 constructs, p.Tyr923Asp and 
p.Tyr332Valfs*18, rescued ciliogenesis in 6% of the cells (N = 3 with > 250 cells analyzed per experiment). c Length measurements of the rescued 
cilia based on the IFT88 staining of the cilium. The dots represent individual cells and the horizontal line indicates the mean (N ≥ 75). Significance 
was measured using the unpaired two-tailed t test; wild-type compared to either mutant showed a p < 0.0001. d Ciliary localization of the IFT-B 
protein IFT88. There is a significant increase of cilia displaying a ciliary tip accumulation of IFT88 in both the p.Tyr923Asp (50%) and the p.Y332Vfs*18 
(56%) mutant IFT140 constructs compared to wild-type (23%) (Fisher’s exact two-tailed test showed a p < 0.0001 when comparing either mutant to 
wild-type IFT140). N = 3 with > 50–100 cells per experiment
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on ciliary length were not observed. To exclude that the 
observed retrograde IFT defect is caused by variants 
other than the ones found in IFT140, we additionally per-
formed rescue experiments using CRISPR/Cas9-derived 
Ift140 knockout cells. A significantly higher percentage 
of cilia showed IFT88 tip accumulation in Ift140 knock-
out cells transfected with an IFT140 construct carrying 
the patient p.Tyr923Asp or the p.Tyr332Valfs*18 variants 
compared to wild-type IFT140.
Recent publications have shown that the IFT-A complex 
is not only required for retrograde transport, but that it 
is also essential for the ciliary entry of transmembrane 
proteins, including G protein-coupled receptors (GPCRs), 
important for the transduction of intercellular signals [27, 
28]. Cells defective for TTC21B, part of the peripheral 
subcomplex, showed an accumulation of both IFT-A and 
B at the ciliary tip, and a ciliary enrichment of GPCRs. 
Interestingly, cells defective in IFT-A core component 
WDR19 showed an accumulation of IFT-B proteins at 
the ciliary tip, while IFT-A components and GPCRs were 
absent from the cilium [28]. This means that disruption 
of the IFT-A core subcomplex abolishes IFT-A complex 
formation and its entry into the cilium, not only result-
ing in defective retrograde IFT, but also withholding cili-
ary entry of GPCRs. Our data provide evidence that the 
defective retrograde IFT seen in the patient is caused by 
the mutated IFT140, though the possible effects on the 
ciliary entry of GPCRs were not assessed in this study.
Combining the results of clinical, molecular, and func-
tional studies, we conclude that the patient carries two 
pathogenic variants in IFT140 underlying SRTD9 also 
called Mainzer–Saldino syndrome. We suggest that vari-
ants in IFT140 may cause progressive hearing impair-
ment, as well, and that this could be part of the MZSDS 
phenotype. The classic MZSDS phenotype includes renal 
failure, which is not seen in the patient until 1.5  years 
of age. Therefore, monitoring of renal function of the 
patient needs to be continued in the future as this may 
decline over time.
Conclusion
In this study, two novel IFT140 variants were detected by 
diagnostic WES, suggestive for MZSDS, in a 1-year-old 
girl with skeletal, retinal, and hearing abnormalities. We 
used a non-invasive technique to obtain patient-derived 
cells to study the pathogenicity of the IFT140 variants 
in vitro. URECs from the patient displayed defective ret-
rograde IFT that is most likely caused by the detected 
IFT140 variants. Rescue experiments with p.Tyr923Asp 
or p.Tyr332Valfs*18 mutant IFT140 constructs in 
CRISPR/Cas9-derived Ift140 knock out cells also showed 
retrograde IFT defects, confirming the pathogenicity 
of the variants. URECs provide a great source to assess 
the pathogenicity of nonsense, missense, and splice site 
variants found with genetic testing. The combination of a 
thorough clinical examination, genetic testing, and func-
tional studies established a definitive diagnosis of SRTD9.
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